No registrations found.
ID
Source
Brief title
Health condition
(Neurological development)
Sponsors and support
Intervention
Outcome measures
Primary outcome
Neurological Development of the baby (Neurological Optimality Score and General Movements).
Secondary outcome
1. Mood, cognitive functioning and sleeping rhythm of the mother;
2. LCP status in red blood cells of mother (16th and 36th week) and child (12 weeks after birth), umbilical cord, breast milk (2 and 12 weeks after birth).
Background summary
Helathy pregnant women are included prior to the 16th week of pregnancy and are followed till 12 weeks postpartum. During the whole period they have to take the supplement provided and the effect on nuerological development is judged.
Study objective
DHA and AA during pregnancy shall lead to a better neurological development of the baby and possibly to better mood, cognitive functioning and sleeping rhythm of the mother.
Study design
N/A
Intervention
Everybody recieves a multivitamin supplement (desgined for pregnant women).
Next to that we compare placebo vs DHA vs DHA/AA.
P.O. box 30001
Saskia A. Goor, van
Hanzeplein 1
Groningen 9700 RB
The Netherlands
+31 (0)50 3610399
s.a.van.goor@lc.umcg.nl
P.O. box 30001
Saskia A. Goor, van
Hanzeplein 1
Groningen 9700 RB
The Netherlands
+31 (0)50 3610399
s.a.van.goor@lc.umcg.nl
Inclusion criteria
1. Apparently healthy pregnant women;
2. Para 0 or 1;
3. Inclusion should take place prior to the 16th week of pregnancy.
Exclusion criteria
1. Hyperemesis Gravidarum
2. Vegetarian of Vegan;
3. Pregnant with twins;
4. Diabetes Mellitus type 1;
5. Usage of helath supplements with fatty acids, tryptophan or melatonin.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL328 |
| NTR-old | NTR366 |
| Other | : N/A |
| ISRCTN | ISRCTN58176213 |